INCIDENCE, RISK-FACTORS, AND OUTCOME OF SEVERE SEPSIS AND SEPTIC SHOCK IN ADULTS - A MULTICENTER PROSPECTIVE-STUDY IN INTENSIVE-CARE UNITS

被引:783
作者
BRUNBUISSON, C
DOYON, F
CARLET, J
DELLAMONICA, P
GOUIN, F
LEPOUTRE, A
MERCIER, JC
OFFENSTADT, G
REGNIER, B
机构
[1] HOP HENRI MONDOR, SERV REANIMAT MED, F-94010 CRETEIL, FRANCE
[2] HOP ST JOSEPH, SERV REANIMAT MED, PARIS, FRANCE
[3] HOP ROBERT DEBRE, SERV REANIMAT MED, PARIS, FRANCE
[4] HOP ST ANTOINE, SERV REANIMAT MED, PARIS, FRANCE
[5] HOP BICHAT CLAUDE BERNARD, SERV REANIMAT MED, PARIS, FRANCE
[6] HOP ARCHET, SERV REANIMAT MED, NICE, FRANCE
[7] HOP LA TIMONE, SERV REANIMAT MED, MARSEILLE, FRANCE
[8] DIRECT GEN SANTE, BUR MALAD TRANSMISSIBLES, PARIS, FRANCE
[9] INST GUSTAVE ROUSSY, DEPT BIOSTAT, INSERM, U351, VILLEJUIF, FRANCE
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1995年 / 274卷 / 12期
关键词
D O I
10.1001/jama.274.12.968
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To examine the incidence, risk factors, and outcome of severe sepsis in intensive care unit (ICU) patients. Design and Setting.-Inception cohort study from a 2-month prospective survey of 11828 consecutive admissions to 170 adult ICUs of public hospitals in France. Patients.-Patients meeting clinical criteria for severe sepsis were included and classified as having documented infection tie, documented severe sepsis, n=742), or a clinical diagnosis of infection without microbiological documentation (ie, culture-negative severe sepsis, n=310). Main Outcome Measures.-Hospital and 28-day mortality after severe sepsis. Results.-Clinically suspected sepsis and confirmed severe sepsis occurred in 9.0 (95% confidence interval [CI], 8.5 to 9.5) and 6.3 (95% CI, 5.8 to 6.7) of 100 ICU admissions, respectively. The 28-day mortality was 56% (95% CI, 52% to 60%) in patients with severe sepsis, and 60% (95% CI, 55% to 66%) in those with culture-negative severe sepsis, Major determinants of both early (<3 days) and secondary deaths in the whole cohort were the Simplified Acute Physiology Score (SAPS) II and the number of acute organ system failures, Other risk factors for early death included a low arterial blood pH (<7.33) (P<.001) and shock (P=.03), whereas secondary deaths were associated with the admission category (P<.001), a rapidly or ultimately fatal underlying disease (P<.001), a preexisting fiver (P=.01), or cardiovascular (P=.002) insufficiency, hypothermia (P=.02), thrombocytopenia (P=.01), and multiple sources of infection (P=.02). In patients with documented sepsis, bacteremia was associated with early mortality (P=.03). Conclusions.-Only three of four patients presenting with clinically suspected severe sepsis have documented infection. However, patients with clinically suspected sepsis but without microbiological documentation and patients with documented infection share common risk factors and are at similarly high risk of death, In addition to the severity of illness score, acute organ failures and the characteristics of underlying diseases should be accounted for in stratification of patients and outcome analyses.
引用
收藏
页码:968 / 974
页数:7
相关论文
共 31 条
  • [1] A CRITICAL-EVALUATION OF NEW AGENTS FOR THE TREATMENT OF SEPSIS
    BONE, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (12): : 1686 - 1691
  • [2] SEPSIS SYNDROME - A VALID CLINICAL ENTITY
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. CRITICAL CARE MEDICINE, 1989, 17 (05) : 389 - 393
  • [4] BRESLOW NE, 1980, STATISTICAL METHODS
  • [5] BRUNBUISSON C, 1994, ARCH INTERN MED, V154, P2484
  • [6] COMETTA A, 1992, NEW ENGL J MED, V327, P234
  • [7] COX DR, 1972, J R STAT SOC, V34, P248
  • [8] DEAN AD, 1993, EPI INFO VERSION 5 1
  • [9] RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISHER, CJ
    DHAINAUT, JFA
    OPAL, SM
    PRIBBLE, JP
    BALK, RA
    SLOTMAN, GJ
    IBERTI, TJ
    RACKOW, EC
    SHAPIRO, MJ
    GREENMAN, RL
    REINES, HD
    SHELLY, MP
    THOMPSON, BW
    LABRECQUE, JF
    CATALANO, MA
    KNAUS, WA
    SADOFF, JC
    ASTIZ, M
    CARPATI, C
    BONE, RC
    FREIDMAN, B
    MURE, AJ
    BRATHWAITE, C
    SHAPIRO, E
    MELHORN, L
    TAYLOR, R
    KEEGAN, M
    OBRIEN, J
    SCHEIN, R
    PENA, M
    WASSERLOUF, M
    OROPELLO, J
    BENJAMIN, E
    DELGUIDICE, R
    EMMANUEL, G
    LIE, T
    ANDERSON, L
    MARSHALL, J
    DEMAJO, W
    ROTSTEIN, O
    FOSTER, D
    ABRAHAM, E
    MIDDLETON, H
    PERRY, C
    LEVY, H
    FRY, DE
    SIMPSON, SQ
    CROWELL, RE
    NEIDHART, M
    STEVENS, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23): : 1836 - 1843
  • [10] A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS
    GREENMAN, RL
    SCHEIN, RMH
    MARTIN, MA
    WENZEL, RP
    MACINTYRE, NR
    EMMANUEL, G
    CHMEL, H
    KOHLER, RB
    MCCARTHY, M
    PLOUFFE, J
    RUSSELL, JA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08): : 1097 - 1102